Bruze Lab Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 25-12-2024
- Paid Up Capital ₹ 0.10 M
as on 25-12-2024
- Company Age 10 Year, 11 Months
- Last Filing with ROC 31 Mar 2019
- Satisfied Charges ₹ 1.50 M
as on 25-12-2024
- Revenue -91.04%
(FY 2019)
- Profit 36.46%
(FY 2019)
- Ebitda 62.72%
(FY 2019)
- Net Worth -137.89%
(FY 2019)
- Total Assets -5.20%
(FY 2019)
About Bruze Lab
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹1.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Anshu Rai, Prabhudutt Upadhyay, and Ritesh Singh serve as directors at the Company.
- CIN/LLPIN
U24296MH2014PTC251724
- Company No.
251724
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jan 2014
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Bruze Lab Private Limited offer?
Bruze Lab Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine, Digestive System Drugs & Medicines, Digestive Drugs, Nutraceuticals & Dietary Supplements, Nutritional Supplements.
Who are the key members and board of directors at Bruze Lab?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ritesh Singh  | Director | 01-Feb-2017 | Current |
| Prabhudutt Upadhyay | Director | 15-Sep-2018 | Current |
| Anshu Rai | Director | 04-Jan-2014 | Current |
Financial Performance of Bruze Lab.
Bruze Lab Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 91.04% decrease. The company also saw a substantial improvement in profitability, with a 36.46% increase in profit. The company's net worth observed a substantial decline by a decrease of 137.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bruze Lab?
In 2019, Bruze Lab had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 02 Feb 2017 | ₹1.50 M | Satisfied |
How Many Employees Work at Bruze Lab?
Unlock and access historical data on people associated with Bruze Lab, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bruze Lab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bruze Lab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
